Abstract Menkes disease (MD) is an X-linked recessive disorder characterized by copper deficiency resulting in a diminished function of copper-dependent enzymes. Most MD patients die in early childhood, although mild forms of MD have also been described. A diversity of mutations in the gene encoding of the Golgi-resident copper-transporting P 1B -type ATPase ATP7A underlies MD. To elucidate the molecular consequences of the ATP7A mutations, various mutations in ATP7A associated with distinct phenotypes of MD (L873R, C1000R, N1304S, and A1362D) were analyzed in detail. All mutants studied displayed changes in protein expression and intracellular localization parallel to a dramatic decline in their copper-transporting capacity compared to ATP7A the wild-type. We restored these observed defects in ATP7A mutant proteins by culturing the cells at 30°C, which improves the quality of protein folding, similar to that which as has recently has been demonstrated for misfolded ATP7B, a copper transporter homologous to ATP7A. Further, the effect of the canine copper toxicosis protein COMMD1 on ATP7A function was examined as COMMD1 has been shown to regulate the proteolysis of ATP7B proteins. Interestingly, in addition to adjusted growth temperature, binding of COMMD1 partially restored the expression, subcellular localization, and copper-exporting activities of the ATP7A mutants. However, no effect of pharmacological chaperones was observed. Together, the presented data might L. W. J. Klomp and B. van de Sluis contributed equally to this work.
provide a new direction for developing therapies to improve the residual exporting activity of unstable ATP7A mutant proteins, and suggests a potential role for COM-MD1 in this process. 
Introduction
The transition metal copper is an essential trace element required for a range of cellular processes, including neurotransmitter synthesis, mitochondrial respiration, antioxidant defense, connective tissue formation, pigmentation, peptide amidation, and iron metabolism (reviewed by [1] ). The significance of copper is dramatically illustrated by the X-linked recessive disorder Menkes disease (MD; OMIM #309400), which is characterized by copper deficiency (reviewed by [2] [3] [4] ). Based on the severity of the phenotype, three classes of MD can be distinguished. Classical MD patients die in early childhood and suffer from severe mental retardation accompanied by epileptic insults, growth retardation, hypothermia, hypopigmentation, laxity of skin and joints, and the typical ''kinky'' or steely hair [4] . Patients displaying less severe or even no neurological defects are classified as mild MD or occipital horn syndrome (OHS), in which the clinical features of OHS are primarily related to defects in connective tissue formation [4] . MD results from mutations in ATP7A, encoding a 165-kDa copper-transporting P 1B -type ATPase [5] [6] [7] [8] [9] [10] . Although the copper uptake from the diet into enterocytes is not disturbed in patients with MD, dysfunction of ATP7A affects copper transport across the intestinal mucosa into the blood and across the blood-brain barrier, leading to copper deficiency in many tissues. ATP7A resides in the trans-Golgi network (TGN), where it mediates copper incorporation into copper-dependent enzymes such as tyrosinase, lysyl oxidase, and peptidyla-monooxygenase. Upon increasing copper concentrations, ATP7A translocates to the plasma membrane (PM) to facilitate cellular copper excretion [2, 11, 12] . ATP7A missense mutations within conserved regions of the P 1B -type ATPase family generally lead to the development of MD, and are associated with dysregulation of ATP7A protein synthesis, stabilization, trafficking, intracellular localization, copper-transporting capacity, and posttranslation modifications (reviewed by [3] ). Indeed, mutations in the DKTG-motif (Fig. 1a) , containing a conserved aspartic acid residue indispensable for ATP7A activity, affect the copper-induced translocation of ATP7A from the TGN to the PM. A comparable phenotype is seen when the copper-binding CPC-motif (Fig. 1a) , characteristic for heavy metal transporting P-type ATPases, is mutated. However, a clear correlation between mutations in ATP7A and MD phenotype has not yet been identified [10] .
ATP7A is highly homologous to ATP7B, which is another member of the P 1B -type ATPase family. ATP7B is involved in copper export from hepatocytes into the bile [2, 3] . Mutations in ATP7B are associated with the hepatic copper overload disorder Wilson's disease (WD; OMIM #277900), and can lead to misfolded, unstable proteins that mislocalize and consequently are impaired in their coppertransporting function. Interestingly, these defects can be partially restored by adjusting growth temperature or by addition of pharmacological chaperones [13] . In addition, we have previously demonstrated a role for COMMD1, encoded by the canine copper toxicosis gene COMMD1, in ATP7B protein stability. We speculated that COMMD1 mediates the proteolysis of misfolded, newly synthesized ATP7B proteins [14] , and thus might be involved in the pathogenesis of WD.
In the present study, we characterized the molecular consequences of a number of ATP7A mutations that are associated with distinct phenotypes of MD (L873R, C1000R, N1304S, and A1362D). We investigated whether defects in mutant protein expression, subcellular localization, and copper-transporting function as a result of the mutation can be improved, similar as was previously demonstrated for ATP7B. In addition, the effect of COMMD1 on the molecular function of ATP7A WT and mutants was studied. ? ion. The nucleotide-binding domain, containing the conserved SEHPL-motif and DKTG-motif, is located in the cytosolic loop between TMD 6 and 7. After ATP binding and hydrolysis by the SEHPL-motif, the aspartic acid in the DKTG-motif accepts the phosphate group, resulting in the formation of a phosphorylated intermediated ATP7A protein. The actuator domain contains the TGE-motif, which is involved in dephosphorylation of the protein. The LL-motif at the end of the C-terminus regulates retrograde transport of the protein from vesicles or the plasma membrane (PM) to the trans-Golgi network (TGN). ATP7A mutations studied in this report are depicted with a yellow star. b HEK293T cells were transiently transfected with constructs encoding pcDNA (empty vector; EV), ATP7A-flag wild-type (WT) or mutant (L873R, C1000R, 1304S, and A1362D) as indicated. Protein lysates (30 lg) were analyzed by SDS-PAGE and immunoblotting (IB) using antibodies directed against the Flag-tag or a-Tubulin as indicated on the right side of the figure. c mRNA abundance of ATP7A-Flag WT or mutants, expressed in HEK293T cells, was analyzed by means of qRT-PCR as described in ''Materials and methods''. The data represent mean ± SD of triplicate measurements for each condition. The data were corrected for transfection efficiency and GAPDH expression, and normalized to WT. d HEK293T cells were transiently transfected with EV or with constructs encoding ATP7A-Flag WT and mutants, GST only or ATOX1-GST, as indicated above the figure. Cells were incubated overnight under basal conditions (-) or with 150 lM CuCl 2 . Cells were lysed (lysis buffer supplemented with 1 mM CuCl 2 ) and GST fusion proteins were precipitated using glutathione Sepharose (GSH) beads. Precipitates (GST PD) or total cell lysates (Input; 30 lg) were analyzed by SDS-PAGE and IB using antibodies directed against the Flag-tag or GST COMMD1 modulates ATP7A function 151
Materials and methods

Reagents
The following antibodies were used for immunoprecipitation and immunoblotting: rabbit-anti-COMMD1 antiserum [15] Monoclonal HEK293T cell lines, stably transfected with pSUPER-RETRO vector (shControl) or a plasmid encoding a short hairpin RNA (shRNA) targeting the COMMD1 mRNA sequence (shCOMMD1), were described previously [17] and maintained in HEK293T medium supplemented with 1 lg/ll puromycin dihydrochloride (Sigma-Aldrich). In various experiments, cells were incubated overnight with 10-150 lM CuCl 2 (Sigma-Aldrich) or 10-200 lM bathocuproinedisulfonic acid (BCS; SigmaAldrich), respectively, prior to lysis or fixation.
MEFs were isolated from E14 embryos carrying loxP restriction sites around the first exon of Commd1. Loss of Commd1 expression was accomplished as described previously [18] .
Cells were transiently transfected by the calcium phosphate precipitation method as described elsewhere [19] . For cell surface biotinylation and immunofluorescence assays, cells were transfected with linear polyethylenimine (PEI; Polysciences, Warrington, PA, USA) at a 1:5 DNA:PEI ratio in serum-free medium. Transfection of siRNA ON-TARGETplus SMARTpools was performed by means of Lipofectamine RNAiMAX (Invitrogen Life Technologies Corporation), according to the manufacturer's protocol. Cells were harvested 48 h after transfection for biochemical analysis.
Constructs pEBB-HA-COMMD1 and pEBB-COMMD1-GST constructs have been described previously [20] . pEBB-COMMD1-GST a.a. 1-118 and a.a. 119-190 deletion constructs were kindly provided by Dr. E. Burstein (Dallas, TX, USA) [21] . pcDNA4-ATP7A-Myc construct was obtained from Dr. A. Monaco (Oxford, UK) [22] in which the Flag-tag sequence was introduced in front of the Myc-tag by the Quickchange site-directed mutagenesis method (Stratagene, La Jolla, CA, US). ATP7A-Flag deletion constructs (a.a. 1-654, a.a. 795-94, a.a. 1,008-1,368, and a.a. 1,411-1,500) were subcloned into the pEBB-Flag vector. MD-associated mutations (L873R, C1000R, N1304S, and A1362D) were introduced in pcDNA4-ATP7A-Flag-Myc by the Quickchange sitedirected mutagenesis method (primer sequences available upon request). Sequences were verified by automated sequence analysis. The pG3L3-E1b-TATA-4MRE construct (MRE luciferase reporter) has been described previously [23] , whereas the pRL-TK construct was obtained commercially from the Promega Corporation (Madison, WI, USA).
Quantitative reverse transcriptase PCR (qRT-PCR)
Total RNA was isolated from cells by means of TRIZOL Ò (Invitrogen Life Technologies Corporation). cDNA synthesis was performed using random hexamers and Super Script II reverse transcriptase (Invitrogen Life Technologies Corporation). mRNA expression of ATP7A was analyzed by quantitative PCR using Sybrgreen (Bio-Rad Laboratories Inc, Hercules, CA, USA) and the MyIQ real-time PCR cycler (Bio-Rad) using primers listed in Supplementary  Table 1 . Results were presented as fold induction, and normalized to the expression of GAPDH, which was selected as the most stable reference gene. Zeocin mRNA expression was used as a transfection marker.
Metal-responsive element-luciferase copper biosensor assays
The bioavailability of cytosolic copper was measured by MRE-luciferase copper reporter assays, which were performed as described previously [13, 23] . Briefly, 20,000 HEK293T cells were seeded in 96-well plates and cotransfected with 35 ng pG3L3-E1b-TATA-4MRE construct (MRE-luciferase reporter), 0.25 ng or pRL-TK vector and 0.4 ng empty vector (EV) or pcDNA4-ATP7A constructs as indicated. Cells were incubated overnight with indicated concentration of CuCl 2 , whereafter the cells were rinsed in PBS and harvested in passive lysis buffer (Promega) according to the manufacturer's protocol. Samples were analyzed by luminometry (Berthold Technologies, Bad Wildbad, Germany) using the DualLuciferase reporter system (Promega) for firefly luciferase activity and Renilla luciferase activity, according to the manufacturer's protocol. The RLU (relative light units) were calculated by dividing firefly luciferase measurements by Renilla luciferase measurements. All values were expressed as fold induction relative to ATP7A WT.
GST pull-down assays and immunoblot analysis
Precipitation of GST-tagged proteins by means of GSH-Sepharose beads was performed as described in [24] . In short, transiently transfected cells were rinsed once in PBS prior to lysis in lysis buffer A (25 mM HEPES; pH 7.9, 100 mM NaCl, 1 mM NaEDTA, 1% Triton X-100, 10% glycerol) supplemented with 1 mM Na 3 VO 4 , 1 mM PMSF, 10 mM DTT, and protease inhibitors (Complete; Roche, Basle, Switzerland). For lysis of copper-treated or BCS-treated cells, lysis buffer A was supplemented with 1 mM CuCl 2 or BCS, respectively [14, 25] . Protein concentrations were determined by Bradford Protein Assay (Bio-Rad). In all interaction studies, equal amounts of proteins in lysis buffer A were used for precipitation. Input samples represented approximately 1% of protein amounts used for GST-precipitation. Except for detection of ATP7A, protein lysates were boiled at 95°C prior to gel loading. In all experiments, SDS-PAGE was followed by protein transfer onto nitrocellulose membranes (Schleicher & Schuell's-Hertogenbosch, the Netherlands) for immunoblot analysis.
Cell surface biotinylation assays U2OS cells were used for cell surface biotinylation assays. Cells were incubated under basal conditions, or overnight with 50 lM CuCl 2 as indicated in the experiment. Two days after transfection, proteins present on the cell surface were biotinylated as described in [26] .
Lysyl oxidase activity assays For lysyl oxidase activity assays, 20,000 HEK293T cells, stably transfected with either shControl or shCOMMD1, were seeded in 96-well plates. Upon overnight incubation with 10 and 50 lM BCS, or 0, 10, and 50 lM CuCl 2 , the lysyl oxidase activity was measured according to the manufacturer's protocol using the Amplite TM Fluorimetric Lysyl Oxidase Assay Kit (AAT Bioquest, Inc., Sunnyvale, CA, USA), in which released H 2 O 2 is detected using an Amplite TM HRP substrate. Obtained values were plotted against a lysyl oxidase standard curve.
Indirect immunofluorescence and confocal laserscanning microscopy HEK293T cells were grown on coverslips pre-coated with poly-L-lysine (1:10 dilution, Sigma-Aldrich). Forty-eight hours after transfection, cells were washed once in icecold PBS and fixed using 4% (w/v) paraformaldehyde for 20 min at 4°C. Cells were quenched with 50 mM NH 4 Cl for 5 min at room temperature following blocking and permeabilization using blocking buffer (0.2% (w/v) BSA (Sigma-Aldrich), 0.1% (w/v) saponin (Sigma-Aldrich) in PBS) for 1 h at room temperature in the dark. Immunolabeling was performed in blocking buffer with the indicated primary antibodies for 1 h. After washing three times, secondary labeling was performed with AffiniPure Alexa Fluor Ò 488 or 568 antibodies. DAPI staining was performed in the final wash steps preceding the mounting of coverslips in Fluorsave (VWR International Ltd, Leicestershire, UK). Images were acquired using an LSM710 Meta confocal microscope (Carl Zeiss, Jena, Germany) equipped with a 63X/1.40 N.A. Plan-Apochromat objective by sequential excitation at 408, 488, and 561 nm.
Statistical analysis
Relative protein expressions and interaction strengths were quantified using densitometry (GS-700; Bio-Rad). The quantitative data in this paper are represented as mean ± SD. Statistical evaluation was made using Student's t test and differences were considered to be significant at p \ 0.05.
Results
Menkes disease-associated mutations in ATP7A result in diminished copper-transporting capacities For this study, we selected mutations in ATP7A, which are associated with either classical MD (L873R), mild MD COMMD1 modulates ATP7A function 153 (C1000R and A1362D), or OHS (N1304S and A1362D) (Fig. 1a, yellow stars) . Several features of these mutants have already been reported by MD patient studies and yeast studies (summarized in Table 1 ). However, the detailed molecular consequences of these mutations on ATP7A expression, intracellular localization, and function in eukaryotic cells remain to be determined. First, we determined the expression of the mutant ATP7A proteins relative to the ATP7A wild-type (WT). Transient transfection of HEK293T cells with ATP7A WT or mutant constructs resulted in variable protein expression. Whereas the expression of the L873R and N1304S mutants was more abundant in comparison to WT, a clear decrease in the protein expression of the C1000R and A1362D mutants was observed (Fig. 1b) . Importantly, as shown in Fig. 1c , the differences in protein expression could not be ascribed to alterations in the mRNA expression of the mutants relative to ATP7A WT. Despite their altered protein expression, GST pull-down analysis showed that all ATP7A mutants were still able to interact with the copper chaperone ATOX1 in a copper-dependent manner, similar to that seen for WT protein (Fig. 1d) . Second, we examined whether the mutations affected the copper-induced translocation of ATP7A from the TGN to the PM using indirect immunofluorescence and cell surface biotinylation assays. As shown previously, colocalization of ATP7A WT protein with the TGN marker p230 demonstrated that ATP7A is localized to the TGN under basal conditions ( Fig. 2a; upper frames) . In excess copper, ATP7A WT was completely translocated to the PM ( Fig. 2a; lower frames) . Interestingly, all ATP7A mutant proteins showed an altered subcellular localization compared to WT (Fig. 2b) . In line with previous findings [27] , mutant L873R was found to be constitutively present at the PM. N1304S was localized to the cell periphery and the PM under both conditions. Similar to ATP7A WT, C1000R, and A1362D mutants localized to the TGN; however, upon increasing copper concentrations, all immunoreactivity remained restricted to TGN, and no staining at the PM could be observed, indicating that both proteins failed to translocate to the PM. The PM localization of ATP7A WT and the mutant proteins L873R and N1304S was confirmed by biotinylation assays in U2OS cells. Upon copper incubation, ATP7A WT expression at the PM was markedly enhanced (Fig. 2c) . In agreement with the immunofluorescence data, we demonstrated that mutant L873R is constitutively present on the PM. Similar to ATP7A WT, biotinylation studies of mutant N1304S revealed a copper-induced PM expression, although its occurrence at the PM was already higher compared to WT protein at basal conditions. Interestingly, the re-localization of both mutants from the PM back to the TGN was significantly affected. Mutant L873R remained localized to the PM in conditions of copper depletion, whereas N1304S expression was most abundant in the cell periphery (Fig. 2d) . This indicates that both mutants were drastically impaired in their retrograde trafficking to the TGN.
Third, we investigated whether the copper-transporting activity of the different ATP7A mutants was affected. For this, an established luciferase-based copper biosensor was employed, which has previously been used to characterize the activity of copper transporters, including ATP7B [13, 23] . The copper biosensor design is based on the transactivation of the metallothionein-1 promotor in response to bioavailable cytosolic copper. An increase in the cytosolic copper concentration results in activation of the metal responsive transcription factor 1 (MTF-1), and subsequently promotes the expression of firefly luciferase by binding of MFT-1 to MREs positioned upstream of the firefly luciferase open reading frame in a copper-dependent fashion. In this way, the MRE-luciferase reporter measures the bioavailable cytosolic copper. Upon increasing copper concentrations, empty vector (EV) transfected cells showed a clear and saturable induction of reporter activity (Fig. 3a,  black line) . In the presence of ATP7A WT, the reporter activity was markedly diminished, reflecting ATP7A-dependent export of copper from the cell (Fig. 3a , dark blue line). As shown in Fig. 3a , the copper-transporting capacities of all the mutants were clearly impaired and showed almost a similar induction of the copper reporter activity upon copper stimulation as was seen for EV-transfected cells (Fig. 3a, b) . These data indicate that all ATP7A mutations studied in this paper are associated with aberrant subcellular localization and for some mutations also with reduced protein expression. Consequently, these changes result in almost complete impairment of their copper-transporting capacity.
Mutant protein expression is impaired as a result of aberrant protein folding
In contrast to the enhanced expression of mutants L873R and N1304S, the protein level of mutants C1000R and A1362D was clearly reduced and is likely the result of increased proteolysis. To examine the potential role of proteasomal degradation on the decreased expression of C1000R and A1362D, cells were transfected with each of the mutants and incubated with the proteasomal inhibitor MG132. Blocking the proteasomal activity markedly improved the protein expression of both mutants (Fig. 4a) , and the enhanced proteasomal degradation of C1000R and A1362D mutants might be the result of defective protein folding. To test this hypothesis, we improved the quality of the protein folding by reducing the growth temperature (as shown previously by [13, 26, 28, 29] ). HEK293T cells transiently transfected with either WT or ATP7A mutants C1000R and A1362D were grown at a low temperature (30°C). At 30°C, the expression of ATP7A WT, C1000R, and A1362D mutant proteins was markedly increased compared to cells cultured at 37°C (Fig. 4b) . Next, we investigated the effects of the pharmacological folding chaperones 4-phenyl butyric acid (4-PBA) and curcumin on mutant protein expression. Incubation with 4-PBA or curcumin under conditions previously used to enhance the stability of other mutant P-type ATPases (e.g., ATP7B and ATP8B1) [13, 26] , however, did not enhance the protein expression of ATP7A C1000R and A1362D (data not shown).
Since cellular growth at 30°C restores mutant protein expression, we determined whether protein localization and function can similarly be rescued by lowering the growth temperature. Although the subcellular localization of ATP7A WT protein was unaltered by a lower growth temperature, the intracellular localization of both mutants was clearly normalized. As shown in Figs. 2 and 4c , the expression of the C1000R and A1362D mutants was mainly restricted to the TGN at 37°C, whereas culture at 30°C induced a clear translocation to the cell periphery already at basal conditions (Fig. 4c) . In excess copper, translocation to the PM of mutant A1362D was induced, similarly to ATP7A WT. Remarkably, copper reporter assays at this temperature demonstrated a significant decrease in the induction of the reporter to levels almost comparable to ATP7A WT, indicating a clear enhancement of the copper-transporting function of both ATP7A mutants (Fig. 4d) . These data therefore suggest that the reduced copper-transporting capacities of the C1000R and A1362D mutants result from protein misfolding and subsequent proteasomal degradation or mislocalization.
COMMD1 binds ATP7A and improves the protein expression of ATP7A Previously, we and others have demonstrated that COM-MD1 regulates the proteolysis of a number of proteins, including ATP7B [14, 17, 30, 31] . To investigate whether ATP7A protein stability is also mediated by COMMD1, we studied the effect of COMMD1 on ATP7A expression. Interestingly, overexpression of COMMD1 clearly enhanced the level of both ATP7A WT and mutant proteins (Fig. 5a ). This effect of COMMD1 on ATP7A expression did not result from changes in ATP7A mRNA levels (Fig. 5b) . In concordance, HEK293T cells stably transfected with shRNA targeting COMMD1 sequence (shCOMMD1) showed a decrease in ATP7A protein level (Fig. 5c) , and ATP7A WT and all tested mutants were similarly affected by COMMD1 knockdown. These data were confirmed in HEK293T cells transiently transfected with siRNA targeting COMMD1 expression (Supplementary Fig. 1 ). In addition, shRNA-mediated downregulation of COMMD1 expression in HEK293T cells resulted in a significant decline in the protein level of endogenous ATP7A compared to control cells (Fig. 5d) . Similar results were obtained in mouse embryonic fibroblasts (MEFs) lacking Commd1 expression (Fig. 5d) .
Next, we elucidated to what extent COMMD1 expression affects the cellular copper homeostasis. In line with the observed decline in ATP7A protein level, downregulation of COMMD1 significantly induced the activity of the copper reporter. This suggests that copper efflux from the cell, mediated by ATP7A, is attenuated in COMMD1 depleted cells (Fig. 5e ), but was complemented by exogenous ATP7A (Fig. 5e) . To further corroborate the role of COMMD1 on ATP7A activity, we studied the biosynthesis of active cuproenzyme lysyl oxidase. Lysyl oxidase activity is dependent on the copper-transporting activity of ATP7A [32] . COMMD1 depletion resulted in significant reduction in lysyl oxidase activity in both HEK293T COMMD1 knockdown cells and in Commd1 KO MEFs compared to control cells (Fig. 5f) .
Subsequently, we determined whether COMMD1 also interacts with ATP7A WT and mutant proteins, as has previously been demonstrated for ATP7B [13, 14] . GST PD analyses revealed a clear and specific interaction between COMMD1 and ATP7A WT (Fig. 6a) . Although the expression of ATP7A WT and mutant proteins differed, we could not distinguish any obvious discrepancies in the binding of COMMD1 to ATP7A WT and mutants. Similar to what has been shown for all of the identified COMMD1 protein-protein interactions so far [14, 30, 31, 33, 34] , the binding site for COMMD1 to ATP7A was mapped to the COMM domain of COMMD1 (a.a. residues 119-190; Fig. 6b ), a sequence shared by all ten members of the COMMD protein family. ATP7A domains interacting with COMMD1 were restricted to the N-terminus (a.a. 1-654) and to the cytosolic loop located between trans-membrane domain (TMD) 6 and 7 (a.a. 1,008-1,368) (Fig. 6c) . Since the N-terminus of ATP7A is involved in copper binding, we determined whether the interaction between ATP7A and COMMD1 depended on copper. Upon excess copper or copper depletion by means of BCS, binding of ATP7A to COMMD1 was unaltered while the interaction with ATOX1 could only be detected in conditions of excess copper, suggesting that COMMD1 binds to ATP7A in a copper-independent fashion (data not shown). Altogether, we here illustrate that COMMD1 expression modulates the protein level of both ATP7A WT and mutants, and subsequently cellular copper homeostasis.
COMMD1 ameliorates copper exporting function of ATP7A mutants
We continued to examine the effect of COMMD1 on the subcellular localization and copper-transporting capacity of ATP7A mutant proteins. Similar to the conditions for cellular growth at 30°C, overexpression of COMMD1 induced a marked change in the localization of the mutants C1000R and A1362D from the TGN to the cell periphery and PM, respectively (Fig. 7) . COMMD1 did not affect the localization of the L873R and N1304S mutants (data not shown). Additionally, no effect of COMMD1 on the cellular localization of ATP7A was established ( Supplementary Fig. 2) . Interestingly, as a consequence of improved protein expression and localization, COMMD1 ameliorated the copper exporting function of the ATP7A mutants as reflected by decreased induction of the copper reporter activity (Fig. 8a) . Indeed, upon co-expression of COM-MD1, a significant reduction in the copper reporter activity (approximately 29 and 36%) was observed in cells expressing C1000R or N1304S mutant proteins, respectively (Fig. 8a) . Exogenous COMMD1 in cells expressing mutants L873R and A1362D resulted in a trend towards an improved copper exporting capacity, although these changes were not significant. In line with these results, downregulation of COMMD1 expression led to a significant further increase in the induction of copper reporter activity for almost all ATP7A mutants (Fig. 8b) .
Discussion
MD is caused by mutations in the ATP7A gene, however, the molecular consequence of these mutations is still unclear [5] [6] [7] [8] [9] [10] . Here, we investigated four mutations in ATP7A associated with three distinct MD phenotypes; classical MD (severe MD), mild MD with long survival, and OHS. The characteristics of the selected ATP7A mutants on protein expression, intracellular localization, and copper transport were studied, and summarized in Table 2 . Our most important observation was the clear improvement of the copper-transporting function of some of these ATP7A mutants in response to cellular growth at a low temperature (30°C) and upon COMMD1 expression. Two of the four mutations studied (C1000R and A1362D) resulted in decreased expression of the mutant ATP7A protein. This reduced expression was associated with enhanced proteasomal degradation rates, presumably as a result of protein misfolding. Indeed, improving protein folding by cellular growth at 30°C resulted in a significant increase in the protein expression of these mutants, and almost completely restored their copper transport activity. These findings are consistent with previous findings on other P-type ATPases, including ATP7B and ATP8B1 [13, 26] . Whereas misfolding of proteins is frequently accompanied by aberrant intracellular localization, the ATP7A C1000R and A1362D mutants were properly localized to the TGN, but failed to translocate to the plasma membrane upon increased medium copper concentrations (previously shown for C1000R by [27] ). In contrast to ATP7B and ATP8B1, no effect of the pharmacological chaperones 4-PBA and curcumin on ATP7A C1000R and A1362D mutant function was observed. Yet, similar to 4-PBA and curcumin, other compounds have been described as enhancing protein folding and stability (e.g., dimethyl sulfoxide (DMSO), trimethylamine N-oxide (TMAO), and glycerol), and therefore it might be interesting to evaluate their potential in improving ATP7A expression and function.
As a consequence of the mutations L873R and N1304S, associated with severe MD and OHS, respectively, the COMMD1 modulates ATP7A function 159 subcellular localization of these ATP7A mutant proteins was disturbed, and the copper export capacity was almost completely abolished. The expression of these mutant proteins was, however, comparable to ATP7A WT or even enhanced. These results on mutant L873R are in line with the data recently published by Petris et al. [27] . Consistent in combination with ATP7A-Flag. Cells were lysed and a GST pulldown assay was performed and analyzed as described in Fig. 1d . c HEK293T cells were transiently transfected with constructs encoding COMMD1-GST and ATP7A-Flag N-terminal sequence (a.a. 1-164), internal loop TMD4-5 (a.a. 795-944), internal loop TMD6-7 (a.a. 1,008-1,368) or C-terminal region (a.a. 1,411-1,500). Cells were lysed, and a GST pull-down assay was performed and analyzed as described in Fig. 1d Fig . 7 Copper-induced trafficking of ATP7A mutants is largely restored by COMMD1. Localization of ATP7A mutants C1000R and A1362D was determined in HEK293T cells, transiently transfected with EV or HA-COMMD1. Cells were incubated overnight under basal conditions or with 150 lM CuCl 2 . Cells were subsequently analyzed by indirect confocal immunofluorescence using antibodies against the Flag-tag (green). Nuclei were stained with DAPI (blue). Bars: 10 lm with the notion that these mutations are located in highly conserved functional domains essential for ATPase activity of the copper pump, we suggest that they may not induce aberrant folding, but rather result in a protein with severely affected or completely abolished copper-transporting activity. The aberrant expression of these proteins at the cell periphery under copper depleted conditions would explain the disrupted copper transfer into the secretory pathway for the biosynthesis of copper-dependent enzymes. However, in contrast to mutant L873R, N1304S mainly resides in the cell periphery and is to some extent also localized at the PM under copper-depleted or basal conditions. Additionally, in excess copper, this mutant shows a relatively normal copper response. These data suggest that this mutation does not completely abrogate the biosynthetic function of ATP7A, which correlates perfectly with its mild atypical Menkes disease phenotype. However, generally, it is currently still challenging to identify any genotype-phenotype correlation in MD patients, since a third of the mutations described are de novo, and there is inter-and intra-familial variability. For example, the A1362D mutation is associated with mild MD as well as with OHS in two different families [6, 35] . In addition, the R844H mutation has been identified in patients in one family with both a classical MD and mild MD phenotype [6, 36, 37] , whereas S637L and A1362V mutations are associated with all three MD phenotypes both within and between families [35, 38, 39] . The mechanisms behind these phenotypic variations are unknown, but they point to genetic and/or environmental factors that modulate disease severity.
Our data also demonstrate a novel role for COMMD1 in the protein expression and function of ATP7A mutant proteins. COMMD1 expression enhanced ATP7A levels, improved the subcellular localization, and ameliorated the copper exporting capacities of the ATP7A mutants. Since COMMD1 expression and cellular growth at 30°C both improved the molecular function of ATP7A mutants in an almost similar manner, we propose that COMMD1 might be involved in protein folding of ATP7A, and consequently in ATP7A stability, expression and function. Since decreased expression of COMMD1 clearly exacerbates the impaired function of ATP7A mutant proteins, it would be interesting to determine whether genetic variants of COMMD1 are associated with distinct MD phenotypes. We further evidently demonstrated that loss of COMMD1 expression attenuates ATP7A protein level and cellular copper homeostasis, indicating COMMD1 as novel modulator of ATP7A function.
In conclusion, in addition to mislocalization, our study clearly demonstrates that a number of mutations in ATP7A also display a reduced protein expression, most likely as a result of misfolding. Improving the protein folding ameliorates the copper exporting activity, and, depending on the molecular consequence of the mutation, might provide a new direction for therapeutic strategies to treat MD. Additionally, we also show a novel role for COMMD1 in regulating the copper-transporting function of ATP7A WT and four ATP7A mutants associated with MD, and implicate COMMD1 as a potential modifier in MD pathogenesis. 
